Diabetes, Metabolic Syndrome and Obesity
Volume 17, 2024 - Issue
ORIGINAL RESEARCH
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus
Yujian Shao1 Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China;2 Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd, Hangzhou, Zhejiang, People’s Republic of China
https://orcid.org/0000-0001-9840-5396
https://orcid.org/0000-0001-9840-5396, Yonglu Chen2 Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd, Hangzhou, Zhejiang, People’s Republic of Chinahttps://orcid.org/0009-0005-5859-2023
https://orcid.org/0009-0005-5859-2023, Mingyue Zhu3 First Research Institute, Zhejiang Heze Pharmaceutical Technology Co., Ltd, Hangzhou, Zhejiang, People’s Republic of Chinahttps://orcid.org/0009-0002-8030-2705
https://orcid.org/0009-0002-8030-2705, , , , , , Jing Huang3 First Research Institute, Zhejiang Heze Pharmaceutical Technology Co., Ltd, Hangzhou, Zhejiang, People’s Republic of Chinahttps://orcid.org/0009-0002-2320-5087
https://orcid.org/0009-0002-2320-5087, & Yanshan Huang2 Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-8891-9518
https://orcid.org/0000-0002-8891-9518 show all